What the FDA says it is changing about infant-formula recalls after the ByHeart botulism outbreak

The practical takeaway for families is this: the Food and Drug Administration says an infant-formula recall cannot stop at the manufacturer. If recalled cans or packets are still being sold in stores or online, the danger is not over.

That matters because the agency says recalled ByHeart formula was still found for sale after the November 2025 recall tied to a multistate infant botulism outbreak. CDC now says the outbreak is over, with final case data dated February 26, 2026: 48 infants were hospitalized, and no deaths were reported. But the FDA also says the full root cause of the contamination has not been fully determined.

For parents, caregivers, and clinicians, the FDA’s message is not that every unanswered question has been settled. It is that the agency is trying to strengthen what happens after a recall starts, make formula safety information easier to find, and broaden testing and surveillance meant to catch problems earlier.

What FDA says it is changing after the ByHeart outbreak

Based on FDA materials released in late February and March 2026, the agency is emphasizing three practical changes:

More aggressive follow-through when recalled formula remains on shelves
Clearer public-facing formula and recall information for families and clinicians
Expanded sampling, testing, and post-incident surveillance under Operation Stork Speed

In plain language, the FDA is saying a recall is not truly effective if stores, distributors, or online sellers do not act quickly enough.

1) Tougher follow-through when recalled formula remains on shelves

This is the clearest change families may notice.

On its response page, the FDA says it and its state and local partners conducted more than 4,300 recall audit checks during the ByHeart event. Those checks are meant to verify that distributors and retailers received recall notices and actually removed the recalled product from sale.

Even with those efforts, the FDA says it continued receiving reports that recalled ByHeart formula was still available for sale as late as January 18, 2026. The agency says it followed up on those reports by visiting facilities, notifying responsible parties, and issuing four warning letters to retailers.

The broader point is important for parents: a company announcement does not automatically mean every store shelf and every online listing has been cleared. The FDA is signaling that it plans to push harder on retail-level compliance when a recalled infant product keeps showing up in the marketplace.

The agency also said in a December 2025 announcement that recalled formula had remained on shelves for over three weeks in one case and was found in more than 175 locations across 36 states. That helps explain why the FDA is now talking so much about recall effectiveness, not just recall announcements.

2) Easier-to-find formula and recall information for families

The second change is less dramatic but likely more visible to everyday users of the FDA website.

On February 26, 2026, the FDA announced a redesign of its infant-formula web pages. The agency said the goal was to make formula information easier for parents, caregivers, health care providers, and manufacturers to find and use. The update also added a public list of infant formulas available in the U.S. market.

That does not prevent contamination by itself. But it may make it easier for families to check what products are on the market, find recall information faster, and understand where to go for current safety updates.

For caregivers who remember the confusion of past formula disruptions, that may be one of the most immediate changes: a stronger push toward one place for recall notices, product information, and related formula safety updates.

3) Expanded testing and surveillance under Operation Stork Speed

The third change is broader oversight.

Under Operation Stork Speed, the FDA says it is increasing testing of infant formula and ingredients for spore-forming contaminants such as Clostridium botulinum and Bacillus cereus. In February 2026, the agency started a sampling assignment focused on dairy-based ingredients including whole milk powder, nonfat dry milk powder, and whey protein concentrate.

That testing push appears to be part of the FDA’s post-outbreak response. The idea is to learn more about where contamination risks may enter the supply chain and to inform future prevention steps.

Still, families should understand the limit here: expanded sampling and surveillance are not the same thing as proof that future outbreaks will be prevented. The FDA is describing added oversight and investigation, not promising that the underlying problem has been solved.

What happened in the outbreak

CDC says the outbreak is closed. In its final case review, the agency reported 48 total cases, including 28 confirmed and 20 probable cases, across 17 states. All 48 infants were hospitalized and treated, and no deaths were reported.

If you saw earlier totals of 51 infants, that is because CDC says three initially suspected cases were later excluded after medical-record review showed other diagnoses.

Both CDC and FDA say epidemiologic and laboratory evidence linked illnesses to ByHeart Whole Nutrition infant formula. At the same time, the FDA says it has not yet determined the full root cause. In other words, the outbreak was linked to the formula, but investigators are still working out exactly how contamination occurred and whether it entered through ingredients, processing, another step in production, or some combination of factors.

What parents and clinicians should know about symptoms and next steps

Infant botulism is a medical emergency. CDC says symptoms can take as long as several weeks to develop after exposure.

Symptoms to watch for include:

Constipation
Poor feeding or weak sucking
Loss of head control
Difficulty swallowing
Less facial expression
A weak cry
Floppiness or unusual weakness
Breathing trouble

If a baby who may have used recalled formula seems weak, floppy, constipated, has poor feeding, or has trouble breathing, parents should seek urgent medical care right away. CDC tells clinicians not to wait for laboratory confirmation if infant botulism is strongly suspected.

If you still have recalled formula at home, do not use it. Keep the can, packaging, or lot details available if possible, because that information can help when talking with a pediatrician, retailer, or health officials. FDA and CDC recall pages remain the best places to check for the latest official updates.

What is still unresolved

The biggest unanswered question is the exact root cause.

FDA testing found genetic matches among some clinical samples, finished formula samples, and ingredient samples, including organic whole milk powder. But the agency says the detection of C. botulinum in formula and ingredients is complex, and it has identified multiple strains across patients, finished products, and ingredients. That is one reason the FDA says the root cause has not yet been fully determined.

So while the agency is clearly changing how it describes recall oversight and post-incident monitoring, it has not announced a sweeping rewrite of all infant-formula regulation. Nor has it said that the contamination pathway is fully understood.

What this means for readers

For families, the main message is straightforward:

A formula recall is not over just because a company announces it.
The FDA says it is putting more emphasis on whether recalled products actually disappear from stores and online listings.
Parents may also see clearer FDA formula resources and easier-to-find recall information.
Expanded testing under Operation Stork Speed may strengthen oversight, but important questions about prevention and root cause remain open.

If your infant may have used recalled ByHeart formula and now seems weak, floppy, constipated, poorly feeding, or has trouble breathing, get medical care right away. Fast evaluation matters.

Sources

This article is for general informational purposes only and is not medical advice. Research findings can be early, limited, or subject to change as new evidence emerges. For personal guidance, diagnosis, or treatment, consult a licensed clinician. For current outbreak or public health guidance, follow your local health department, the CDC, or another relevant public health authority.